DOCSLIB.ORG

(19) United States (12) Reissued Patent (10) Patent Number: US RE41,998 E Campbell (45) Date of Reissued Patent: Dec

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
(19) United States (12) Reissued Patent (10) Patent Number: US RE41,998 E Campbell (45) Date of Reissued Patent: Dec USOORE41998E (19) United States (12) Reissued Patent (10) Patent Number: US RE41,998 E Campbell (45) Date of Reissued Patent: Dec. 14, 2010 (54) COMPOSITIONS AND METHODS OF 6,534,048 B1 3/2003 Borgman TREATMENT OF SYMPATHETICALLY 6,559,186 B1 5/2003 Campbell MANTAINED PAN 2004/0101582 A1 5, 2004 Wolicki 2004/0132824 A1 7, 2004 Gil et al. (75) Inventor: James N. Campbell, Lutherville, MD FOREIGN PATENT DOCUMENTS (US) DE 2920500 11, 1980 (73) Assignee: Arclon Therapeutics, Inc., Baltimore, EP O 241 050 10, 1987 JP 1216928 8, 1989 MD (US) WO WO92,14453 9, 1992 WO WO 2007/O25613 3, 2007 (21) Appl. No.: 11/123,257 OTHER PUBLICATIONS (22) Filed: May 5, 2005 Indoramin: http://www.netdoctor.co.uk/medicines/ Related U.S. Patent Documents 100000841.html.online retrieved from the internet on Dec. Reissue of: 11, 2008; Jun. 11, 2007: 5 pages. * (64) Patent No.: 6,559, 186 Labetalol: http://www.answers.com/labetalol; online Issued: May 6, 2003 retrieved from the internet on Dec. 11, 2008: Jul. 1, 2002; 7 Appl. No.: 08/286.404 pages. Filed: Aug. 5, 1994 Phenoxybenzamine: http://www.nlm.nih.gov/medlineplus/ druginfo/meds/a882059.html; online retrieved from the U.S. Applications: internet on Dec. 11, 2008; Apr. 1, 2003: 3 pages.* (63) Continuation of application No. 07/747,635, filed on Aug. Medetomidine: http://www.answers.com/topic/medetomi 20, 1991, now abandoned, which is a continuation-in-part of dine-1; online retrieved from the internet on Dec. 11, application No. 07/661.554, filed on Feb. 26, 1991, now abandoned, which is a continuation-in-part of application 2008; 4 pages.* No. 07/485, 156, filed on Feb. 26, 1990, now Pat. No. 5,070, Reserpine: http://www.answers.com/topic/reserpine; on O84. line retrieved from the internet on Dec. 11, 2008; Jul. 1, 2002; 9 pages.* (51) Int. Cl. Ergoloid mesylates: http://web.archive.org/web/ A 6LX 3L/2197 (2006.01) 20071018155031/http:/umm.edu/altimed/drugs/ A63L/47 (2006.01) ergoloid mesylates–048700.htm; online retrieved from the A63L/44 (2006.01) internet on Dec. 15, 2008; Oct. 18, 2007; 6 pages.* A63L/40 (2006.01) Clonidine: http://www.answers.com/topic/clonidine; on A6II 3/34 (2006.01) line retrieved from the internet on Dec. 12, 2008; Jul. 1, A63/55 (2006.01) 2002; 8 pages.* A613 L/35 (2006.01) Bretylium tosylate: http://www.medicinenet.com/brety AOIN 43/42 (2006.01) lium tosylate-injection/article.htm; online retrieved from AOIN 43/38 (2006.01) the internet on Dec. 12, 2008; Mar. 2, 2005; 2 pages.* AOIN 43/26 (2006.01) Captopril; http://www.answers.com/topic/captopril; online AOIN 37/52 (2006.01) retrieved from the internet on Dec. 11, 2008; 9 pages.* AOIN 33/02 (2006.01) Phentolamine; http://www.answers.com/topic/phentola (52) U.S. Cl. .............. 514/817: 514/252.12: 514/253.04; mine; online retrieved from the internet on Dec. 11, 2008: 514/310: 514/354: 514/410; 514/462: 514/634; Jul. 1, 2002; 7 pages.* 514/643; 514/651; 514/654 Prazosin: http://www.nlm.nih.gov/medlineplus/druginfo/ (58) Field of Classification Search .................. 514/634, meds/a88224.5.html; online retrieved from the internet on 514/252.12–13, 252.17, 252.19, 253.03-253.05, Dec. 11, 2008; Mar. 1, 2007: 3 pages.* 514/254.09, 310, 354, 410, 655, 462, 643, Guanfacine: http://www.nlm.nih.gov/medlineplus/druginfo/ 514/651, 654, 252.13, 514 meds/a88224.5.html; online retrieved from the internet on See application file for complete search history. Dec. 11, 2008; Jul. 1, 2002: 6 pages.* (56) References Cited (Continued) Primary Examiner Ernst V Arnold U.S. PATENT DOCUMENTS (74) Attorney, Agent, or Firm Pabst Patent Group LLP 4,201,211 A 5/1980 Chandrasekaran et al. (57) ABSTRACT 4,250,191 A 2/1981 Edwards 4,310,535 A 1/1982 Pierpaoli Sympathetically maintained pain is treated topically by 4,443,441 A 4f1984 Galin administering to the site where sympathetically maintained 4,557,934 A 12/1985 Cooper pain is present an C-1-adrenergic antagonist, C-2-adrenergic 4,742,054 A 5, 1988 Naftchi 4,746.509 A * 5/1988 Haggiage et al. ............ 424/449 agonist, or other drug that depletes or blocks synthesis of 4,801,587 A 1 1989 Voss et al. sympathetic norepinephrine, known collectively as Sym 5,070,084 A 12/1991 Campbell patholytic agents. Chemical formulas for several sym 5.447,947 A 9/1995 Campbell patholytic agents are given. 6,054,461 A 4/2000 Fairbanks et al. 6, 147,102 A 11/2000 Borgman 77 Claims, No Drawings US RE41,998 E Page 2 OTHER PUBLICATIONS Ghostine, et al., “Phenoxybenzamine in the treatment of causalgia” Journal of Neurosurgery 60(6): 1263–1268 Nitroglycerin ointment: http://www.nlm.nih.gov/medline (1984). plus/druginfo/meds/a882346.html; online retrieved from Goodman, et al., The Pharmacological Basis of Therapeu the internet on Dec. 11, 2008: Apr. 1, 2003: 3 pages.* tics (6' Edition) Chapter, 9, pp. 176-210, MacMillan: New Nicergoline: http://www.nlm.nih.gov/medlineplus/druginfo/ York, 1980. meds/a882346.html; online retrieved from the internet on Gonzales, et al., “Production of hyperalgesic prostaglandins Dec. 11, 2008; 4 pages.* by sympathetic postganglionic neurons' J. Neurochem. Rauwolfia: http://www.answers.com/topic/rauwolfia; on 53(5):1595–1598 (1989). line retrieved from the internet on Dec. 11, 2008; 4 pages. * Hobelman, et al., “Use of prolonged sympathetic blockage Engelman. Hypertension, 1988, 11 (suppl II), II–30-II-33).* as an adjunct to Surgery in the patient with sympathetic Nefazodone: http://www.answers.com/topic/labetalol; on maintained pain' Microsurg, 10(2):151–153 (1989). line retrieved from the internet on Dec. 11, 2008; Oct. 25, Index Nominum 1987 pp. 284, Swiss Pharmaceutical Soci 2004; 8 pages.* ety: Zurich, CH, 1987. Trazodone: http://www.answers.com/topic/trazodone; on Ishizuki, "Clinical application of guanethidine ointment to line retrieved from the internet on Dec. 11, 2008; Jul. 1, the treatment of painful states and allodynia Clinical Jour 2002; 13 pages.* nal of Pain 261 1988. Alfuzosin: http://www.answers.com/topic/alfuzosin; on Ito, et al., “Effects of calcium antagonists on alpha-adreno line retrieved from the internet on Dec. 11, 2008; Jun. 25, ceptor mediated vasoconstrictions of the canine intermediate 2003: 4 pages.* auricular artery' Jpn. J. Pharmacol. 44(2):121–126 (1987). Guanadrel: http://www.medicinenet.com/guanadrel-oral/ar Janig, “Causalgia and reflex sympathetic dystrophy: in ticle.htm; online retrieved from the internet on Dec. 12, which way is the sympathetic nervous system involved? 2008; Mar. 2, 2005; 2 pages.* Trends in Neurosciences 8(11):471-477 (1985). Harich Comparative Pain Scale http://www.tipna.org/info/ Krieglstein, “The influence of topically applied bethanidine documents/ComparativePainScale.htm online retrieved on intraocular pressure and pupil in the rabbit' Graefes from the internet on Dec. 12, 2008; Jul. 2002 4 pages. * ARchiv: Ophthalmologie 196(1):31–38 (1975). Byas-Smith, et al., “Transdermal clonidine compared to pla Krieglstein, “The influence of bretylium tosylate on the cebo in painful diabetic neuropathy using a two-stage intraocular pressure of the rabbit' Graefes Archiv. Ophthal mologie 197(2): 153–158 (1975). 'enriched enrollment design”, Pain, 60(3):267–74 (1995). Loh and Nathan, “Painful peripheral states and sympathetic Jarrott, et al., “Clonidine: understanding its disposition, sited blocks' J. Neurol. Neurosurg. Psychiat. 41 (7):664-671 and mechanism of action’. Clin. Exp. Pharmacol. Physiol., (1978). 14(5):471-9 (1987). Merck Manual, Raynard's Phenomenon And Disease, Peltier and Russell, “Recent advances in drug induced neu Holvey, Ed. pp. 487 1972. ropathies”, Curr. Opin. Nerology, 15:633-638 (2002). Naftchi, Chem. Abstr. 110(9):6941Or (1980). Singleton, “Evaluation and treatment of painful peripheral Nakagawa, et al., Chem. Abstr. 111(1): 125267 (1989). polyneuropathy', Semin. Neurol., 25(2): 185–95 (2005). Nakagawa, et al., Chem. Abstr. 110(11):101838Z (1989). Zeigler, et al., “Transdermal clonidine versus placebo in Nakamura, et al., “Peripheral analgesic action of clondine: painful diabetic neuropathy”, Pain, 48(3):403–8 (1992). mediation by release of endogenous enkephalin-like Sub Abram, et al., “Treatment of long-standing causalgia with stances” Eur: J. Pharmacol. 146(2–3), 223-228 (1988). prazosin' Regional Anesthesia 6(2):79-81 (1981). Nakamura, et al., “Peripheral modulation of pain in con Berkow, The Merck Manual of Diagnosis and Therapy, 15" scious guinea pigs: effect of morphine, nalorphine and cloni Edition, pp. 1347–1349, Merch & Co.: Rahway, N.J., 1987. dine' Brazilian Journal of Medical and Biological Research Curtis and Marwah, “Evidence for alpha adrenoceptor 21(3):577–583 (1988). modulation of the nociceptive jaw-opening reflex in rats and Olin, et al., Facts and Comparisons pp. 162e, J.B. Lipincott rabbits' J. Pharmacology Experimental Therapeutics Co.: St. Louis, Mo., 1988. 238:576-579 (1988). Price, et al., “Psychophysical observations on patients with Davis, et al., “Topical application of clonidine relieves hep neuropathic pain relieved by a sympathetic block” Pain eralgesia in patients with sympathetically maintained pain' 36(3):273 288 (1989). Pain 47(3):309-317 (1991). Sagen and Proudfit, “Evidence for pain modulation by pre De Oliveira, et al., “Pain reaction after topical NA and and postsynaptic noradrenergic receptors in the medulla lesions of the obex region in the alert guinea pig Physiology oblongata' Brain Research 331 :285-293 (1985). & Behavior 28(3):413–416 (1982). * cited by examiner US RE41,998 E 1. 2 COMPOSITIONS AND METHODS OF Somatic afferents in the nearby nerve roots and produce pain TREATMENT OF SYMPATHETICALLY relief because of concurrent Somatic blockade, and certain MANTAINED PAN afferents may in addition course with sympathetic efferents.
Load more

Recommended publications
  • Customs Tariff - Schedule
    CUSTOMS TARIFF - SCHEDULE 99 - i Chapter 99 SPECIAL CLASSIFICATION PROVISIONS - COMMERCIAL Notes. 1. The provisions of this Chapter are not subject to the rule of specificity in General Interpretative Rule 3 (a). 2. Goods which may be classified under the provisions of Chapter 99, if also eligible for classification under the provisions of Chapter 98, shall be classified in Chapter 98. 3. Goods may be classified under a tariff item in this Chapter and be entitled to the Most-Favoured-Nation Tariff or a preferential tariff rate of customs duty under this Chapter that applies to those goods according to the tariff treatment applicable to their country of origin only after classification under a tariff item in Chapters 1 to 97 has been determined and the conditions of any Chapter 99 provision and any applicable regulations or orders in relation thereto have been met. 4. The words and expressions used in this Chapter have the same meaning as in Chapters 1 to 97. Issued January 1, 2020 99 - 1 CUSTOMS TARIFF - SCHEDULE Tariff Unit of MFN Applicable SS Description of Goods Item Meas. Tariff Preferential Tariffs 9901.00.00 Articles and materials for use in the manufacture or repair of the Free CCCT, LDCT, GPT, UST, following to be employed in commercial fishing or the commercial MT, MUST, CIAT, CT, harvesting of marine plants: CRT, IT, NT, SLT, PT, COLT, JT, PAT, HNT, Artificial bait; KRT, CEUT, UAT, CPTPT: Free Carapace measures; Cordage, fishing lines (including marlines), rope and twine, of a circumference not exceeding 38 mm; Devices for keeping nets open; Fish hooks; Fishing nets and netting; Jiggers; Line floats; Lobster traps; Lures; Marker buoys of any material excluding wood; Net floats; Scallop drag nets; Spat collectors and collector holders; Swivels.
    [Show full text]
  • )&F1y3x PHARMACEUTICAL APPENDIX to THE
    )&f1y3X PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE )&f1y3X PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 3 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABAMECTIN 65195-55-3 ACTODIGIN 36983-69-4 ABANOQUIL 90402-40-7 ADAFENOXATE 82168-26-1 ABCIXIMAB 143653-53-6 ADAMEXINE 54785-02-3 ABECARNIL 111841-85-1 ADAPALENE 106685-40-9 ABITESARTAN 137882-98-5 ADAPROLOL 101479-70-3 ABLUKAST 96566-25-5 ADATANSERIN 127266-56-2 ABUNIDAZOLE 91017-58-2 ADEFOVIR 106941-25-7 ACADESINE 2627-69-2 ADELMIDROL 1675-66-7 ACAMPROSATE 77337-76-9 ADEMETIONINE 17176-17-9 ACAPRAZINE 55485-20-6 ADENOSINE PHOSPHATE 61-19-8 ACARBOSE 56180-94-0 ADIBENDAN 100510-33-6 ACEBROCHOL 514-50-1 ADICILLIN 525-94-0 ACEBURIC ACID 26976-72-7 ADIMOLOL 78459-19-5 ACEBUTOLOL 37517-30-9 ADINAZOLAM 37115-32-5 ACECAINIDE 32795-44-1 ADIPHENINE 64-95-9 ACECARBROMAL 77-66-7 ADIPIODONE 606-17-7 ACECLIDINE 827-61-2 ADITEREN 56066-19-4 ACECLOFENAC 89796-99-6 ADITOPRIM 56066-63-8 ACEDAPSONE 77-46-3 ADOSOPINE 88124-26-9 ACEDIASULFONE SODIUM 127-60-6 ADOZELESIN 110314-48-2 ACEDOBEN 556-08-1 ADRAFINIL 63547-13-7 ACEFLURANOL 80595-73-9 ADRENALONE
    [Show full text]
  • Chemical Ligand Space of Cereblon Iuliia Boichenko,† Kerstin Bar,̈ Silvia Deiss, Christopher Heim, Reinhard Albrecht, Andrei N
    This is an open access article published under a Creative Commons Attribution (CC-BY) License, which permits unrestricted use, distribution and reproduction in any medium, provided the author and source are cited. Article Cite This: ACS Omega 2018, 3, 11163−11171 http://pubs.acs.org/journal/acsodf Chemical Ligand Space of Cereblon Iuliia Boichenko,† Kerstin Bar,̈ Silvia Deiss, Christopher Heim, Reinhard Albrecht, Andrei N. Lupas, Birte Hernandez Alvarez,* and Marcus D. Hartmann* Department of Protein Evolution, Max Planck Institute for Developmental Biology, Max-Planck-Ring 5, 72076 Tübingen, Germany *S Supporting Information ABSTRACT: The protein cereblon serves as a substrate receptor of a ubiquitin ligase complex that can be tuned toward different target proteins by cereblon-binding agents. This approach to targeted protein degradation is exploited in different clinical settings and has sparked the development of a growing number of thalidomide derivatives. Here, we probe the chemical space of cereblon binding beyond such derivatives and work out a simple set of chemical requirements, delineating the metaclass of cereblon effectors. We report co-crystal structures for a diverse set of compounds, including commonly used pharmaceuticals, but also find that already minimalistic cereblon-binding moieties might exert teratogenic effects in zebrafish. Our results may guide the design of a post-thalidomide generation of therapeutic cereblon effectors and provide a framework for the circumvention of unintended cereblon binding by negative design
    [Show full text]
  • Ep 1553091 A1
    Europäisches Patentamt *EP001553091A1* (19) European Patent Office Office européen des brevets (11) EP 1 553 091 A1 (12) EUROPEAN PATENT APPLICATION published in accordance with Art. 158(3) EPC (43) Date of publication: (51) Int Cl.7: C07D 263/32, C07D 417/14, 13.07.2005 Bulletin 2005/28 C07D 333/20, C07D 413/12, C07D 417/06 (21) Application number: 04726765.3 (86) International application number: (22) Date of filing: 09.04.2004 PCT/JP2004/005119 (87) International publication number: WO 2004/089918 (21.10.2004 Gazette 2004/43) (84) Designated Contracting States: • SAKAMOTO, Johei AT BE BG CH CY CZ DE DK EE ES FI FR GB GR Takatsuki-shi, Osaka 569-1125 (JP) HU IE IT LI LU MC NL PL PT RO SE SI SK TR • NAKANISHI, Hiroyuki Designated Extension States: Takatsuki-shi, Osaka 569-1125 (JP) AL HR LT LV MK • NAKAGAWA, Yuichi Takatsuki-shi, Osaka 569-1125 (JP) (30) Priority: 09.04.2003 JP 2003105267 • OHTA, Takeshi 03.06.2003 JP 2003157590 Takatsuki-shi, Osaka 569-1125 (JP) • SAKATA, Shohei (71) Applicant: Japan Tobacco Inc. Takatsuki-shi, Osaka 569-1125 (JP) Tokyo 105-8422 (JP) • MORINAGA, Hisayo Takatsuki-shi, Osaka 569-1125 (JP) (72) Inventors: • IKEMOTO, Tomoyuki (74) Representative: Takatsuki-shi, Osaka 569-1125 (JP) von Kreisler, Alek, Dipl.-Chem. et al • TANAKA, Masahiro Deichmannhaus am Dom, Takatsuki-shi, Osaka 569-1125 (JP) Postfach 10 22 41 • YUNO, Takeo 50462 Köln (DE) Takatsuki-shi, Osaka 569-1125 (JP) (54) HETEROAROMATIC PENTACYCLIC COMPOUND AND MEDICINAL USE THEREOF (57) A 5-membered heteroaromatic ring compound represented by the formula [I] 1 2 4 5 7 wherein V is CH or N; W is S or O; R and R are each H etc.; X is -N(R )-, -O-, -S-, -SO2-N(R )-, -CO-N(R )- etc.; L is EP 1 553 091 A1 Printed by Jouve, 75001 PARIS (FR) (Cont.
    [Show full text]
  • The Organic Chemistry of Drug Synthesis
    The Organic Chemistry of Drug Synthesis VOLUME 2 DANIEL LEDNICER Mead Johnson and Company Evansville, Indiana LESTER A. MITSCHER The University of Kansas School of Pharmacy Department of Medicinal Chemistry Lawrence, Kansas A WILEY-INTERSCIENCE PUBLICATION JOHN WILEY AND SONS, New York • Chichester • Brisbane • Toronto Copyright © 1980 by John Wiley & Sons, Inc. All rights reserved. Published simultaneously in Canada. Reproduction or translation of any part of this work beyond that permitted by Sections 107 or 108 of the 1976 United States Copyright Act without the permission of the copyright owner is unlawful. Requests for permission or further information should be addressed to the Permissions Department, John Wiley & Sons, Inc. Library of Congress Cataloging in Publication Data: Lednicer, Daniel, 1929- The organic chemistry of drug synthesis. "A Wiley-lnterscience publication." 1. Chemistry, Medical and pharmaceutical. 2. Drugs. 3. Chemistry, Organic. I. Mitscher, Lester A., joint author. II. Title. RS421 .L423 615M 91 76-28387 ISBN 0-471-04392-3 Printed in the United States of America 10 987654321 It is our pleasure again to dedicate a book to our helpmeets: Beryle and Betty. "Has it ever occurred to you that medicinal chemists are just like compulsive gamblers: the next compound will be the real winner." R. L. Clark at the 16th National Medicinal Chemistry Symposium, June, 1978. vii Preface The reception accorded "Organic Chemistry of Drug Synthesis11 seems to us to indicate widespread interest in the organic chemistry involved in the search for new pharmaceutical agents. We are only too aware of the fact that the book deals with a limited segment of the field; the earlier volume cannot be considered either comprehensive or completely up to date.
    [Show full text]
  • Un Novedoso Enfoque Para El Diseño De Fármacos Antimicrobianos Asistido Por Computadora
    TOMOCOMD-CARDD: Un Novedoso Enfoque para el Diseño de Fármacos Antimicrobianos Asistido por Computadora Autora: Yasnay Valdés Rodríguez. Tutores: Prof. Dr. Yovani Marrero Ponce. Prof. MSc. Ricardo Medina Marrero. 2005-2006 La ignorancia afirma o niega rotundamente; la ciencia duda… Voltaire (1694-1778) Quiero dedicar este trabajo a todas aquellas personas que me aprecian y desean lo mejor para mi, especialmente a mis padres. A mi padre Dedico este trabajo con mucho amor, por hacerme comprender que siempre se puede llegar mas lejos, y que no hay nada imposible, solamente hay que luchar... A mi madre Por su infinita bondad, por su sacrificio inigualable. A mis familiares Por todo su apoyo y ayuda que me han mostrado incondicionalmente. A mi hermano Por ser mi fuente de inspiración. A la humanidad “...porque si supiera que el mundo se acaba mañana, yo, hoy todavía, plantaría un árbol” Quiero agradecer a todas aquellas personas que me han ayudado a realizar este sueño: A mis padres por todo el sacrificio realizado, y aún parecerles poco, los amo mucho. A mi madre por estar siempre a mi lado en los buenos y malos momentos ayudándome a levantarme en cualquier recaída. A mi padre por guiarme en la vida y brindarme sus consejos siempre útiles, por darme fuerza y vitalidad. A mi mayor tesoro, mi hermano, que me alumbra de esperanza día a día. A mis tías y primos que me ayudaron mucho, aún estando lejos. A mi novio que me apoyo en todas mis decisiones y con paciencia supo ayudarme. A mis tutores y cotutores que siempre me dieron la mano; especialmente a Yovani por su paciencia, a quien debo gran parte de mi formación como profesional por sus exigencias.
    [Show full text]
  • GPCR/G Protein
    Inhibitors, Agonists, Screening Libraries www.MedChemExpress.com GPCR/G Protein G Protein Coupled Receptors (GPCRs) perceive many extracellular signals and transduce them to heterotrimeric G proteins, which further transduce these signals intracellular to appropriate downstream effectors and thereby play an important role in various signaling pathways. G proteins are specialized proteins with the ability to bind the nucleotides guanosine triphosphate (GTP) and guanosine diphosphate (GDP). In unstimulated cells, the state of G alpha is defined by its interaction with GDP, G beta-gamma, and a GPCR. Upon receptor stimulation by a ligand, G alpha dissociates from the receptor and G beta-gamma, and GTP is exchanged for the bound GDP, which leads to G alpha activation. G alpha then goes on to activate other molecules in the cell. These effects include activating the MAPK and PI3K pathways, as well as inhibition of the Na+/H+ exchanger in the plasma membrane, and the lowering of intracellular Ca2+ levels. Most human GPCRs can be grouped into five main families named; Glutamate, Rhodopsin, Adhesion, Frizzled/Taste2, and Secretin, forming the GRAFS classification system. A series of studies showed that aberrant GPCR Signaling including those for GPCR-PCa, PSGR2, CaSR, GPR30, and GPR39 are associated with tumorigenesis or metastasis, thus interfering with these receptors and their downstream targets might provide an opportunity for the development of new strategies for cancer diagnosis, prevention and treatment. At present, modulators of GPCRs form a key area for the pharmaceutical industry, representing approximately 27% of all FDA-approved drugs. References: [1] Moreira IS. Biochim Biophys Acta. 2014 Jan;1840(1):16-33.
    [Show full text]
  • WO 2010/065547 Al
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date 10 June 2010 (10.06.2010) WO 2010/065547 Al (51) International Patent Classification: (74) Agents: AMII, Lisa, A. et al.; Morrison & Foerster LLP, A61M 15/00 (2006.01) A61M 9/00 (2006.01) 755 Page Mill Road, Palo Alto, CA 94304-1018 (US). A61M 16/00 (2006.01) (81) Designated States (unless otherwise indicated, for every (21) International Application Number: kind of national protection available): AE, AG, AL, AM, PCT/US2009/066272 AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, (22) International Filing Date: DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, 1 December 2009 (01 .12.2009) HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, (25) Filing Language: English KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, (26) Publication Language: English NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, (30) Priority Data: SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, 61/1 19,015 1 December 2008 (01 .12.2008) US TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (71) Applicant (for all designated States except US): MAP (84) Designated States (unless otherwise indicated, for every PHARMACEUTICALS, INC. [US/US]; 2400 Bayshore kind of regional protection available): ARIPO (BW, GH, Parkway, Suite 200, Mountain View, CA 94043 (US).
    [Show full text]
  • Fagin-Event-Laurahaas.Pdf
    Theory and Practice: Collaborating with Ron Fagin on Two Projects in Information Integration Laura Haas IBM Fellow and Director, IBM Research Accelerated Discovery Lab The Adventure Begins… 2 Heterogeneous Federation: Garlic Virtual, lazy integration Queries / Results Specified by queries Supports diverse data Query Processing Flexible; low upfront cost; downside may be poor performance Wrapper Wrapper Wrapper Wrapper database File Other systems Apps spreadsheets 3 Our first real applications were in life sciences (pharma) Queries / Results Query Processing Wrapper Wrapper Wrapper Wrapper Ketanserin, 74050-98-9, Ketanserina, Ketanserine, Ketanserinum, Ketanserin tartrate, Medline Perketal, Serefrex, Sufrexal, Taseron, NCBI literature C22H22FN3O3, CHEMBL51, R-41468, CHEBI:6123, R-41,468, Tocris-0908, 3-(2-(4-(4-Fluorobenzoyl)piperidin-1- Bio Assays Chem Compound yl)ethyl)quinazoline-2,4(1H,3H)-dione, Search AC1L1GSK, Spectrum2_001713, EINECS 277- 680-2, Biomol-NT_000096, UNII-97F9DE4CT4 The prototypical query for drug discovery: . “Find a compound with a structure like this one and assay results in this range” . Example: – Show me all the compounds similar to ketanserin that have been tested against members of the serotonin family and have an ic50 < 1E-8 with molecular weight between 375 and 450, and a logP value between 4 and 6 4 With Heterogeneous Sources, You Get Heterogeneous Semantics Lidanserin - Wikipedia, the free encyclopedia https://en.wikipedia.org/wiki/Lidanserin Ketanserin - Wikipedia, the free encyclopedia https://en.wikipedia.org/wiki/Ketanserin . Searching a database for compounds where “375 < Molwt < 450” yields a set Prazosin - Wikipedia, the free encyclopedia https://en.wikipedia.org/wiki/Prazosin Ambrisentan - Wikipedia, the free encyclopedia https://en.wikipedia.org/wiki/Ambrisentan Ambrisentin (378), Prazosin (383), Trimetaphen cansilate (365), Ketanserin (395) .
    [Show full text]
  • Pharmaceutical Appendix to the Tariff Schedule 2
    Harmonized Tariff Schedule of the United States (2007) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2007) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. ABACAVIR 136470-78-5 ACIDUM LIDADRONICUM 63132-38-7 ABAFUNGIN 129639-79-8 ACIDUM SALCAPROZICUM 183990-46-7 ABAMECTIN 65195-55-3 ACIDUM SALCLOBUZICUM 387825-03-8 ABANOQUIL 90402-40-7 ACIFRAN 72420-38-3 ABAPERIDONUM 183849-43-6 ACIPIMOX 51037-30-0 ABARELIX 183552-38-7 ACITAZANOLAST 114607-46-4 ABATACEPTUM 332348-12-6 ACITEMATE 101197-99-3 ABCIXIMAB 143653-53-6 ACITRETIN 55079-83-9 ABECARNIL 111841-85-1 ACIVICIN 42228-92-2 ABETIMUSUM 167362-48-3 ACLANTATE 39633-62-0 ABIRATERONE 154229-19-3 ACLARUBICIN 57576-44-0 ABITESARTAN 137882-98-5 ACLATONIUM NAPADISILATE 55077-30-0 ABLUKAST 96566-25-5 ACODAZOLE 79152-85-5 ABRINEURINUM 178535-93-8 ACOLBIFENUM 182167-02-8 ABUNIDAZOLE 91017-58-2 ACONIAZIDE 13410-86-1 ACADESINE 2627-69-2 ACOTIAMIDUM 185106-16-5 ACAMPROSATE 77337-76-9
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 8,080,578 B2 Liggett Et Al
    USO08080578B2 (12) United States Patent (10) Patent No.: US 8,080,578 B2 Liggett et al. (45) Date of Patent: *Dec. 20, 2011 (54) METHODS FOR TREATMENT WITH 5,998.458. A 12/1999 Bristow ........................ 514,392 BUCNDOLOL BASED ON GENETIC 6,004,744. A 12/1999 Goelet et al. ...... 435/5 6,013,431 A 1/2000 Söderlund et al. 435/5 TARGETING 6,156,503 A 12/2000 Drazen et al. ..... ... 435/6 6,221,851 B1 4/2001 Feldman ... 51446 (75) Inventors: Stephen B. Liggett, Clarksville, MD 6,316,188 B1 1 1/2001 Yan et al. .......................... 435/6 6,365,618 B1 4/2002 Swartz ... 514,411 (US); Michael Bristow, Englewood, CO 6,498,009 B1 12/2002 Liggett ............................. 435/6 (US) 6,566,101 B1 5/2003 Shuber et al. 435,912 6,586,183 B2 7/2003 Drysdale et al. .................. 435/6 (73) Assignee: The Regents of the University of 6,784, 177 B2 8/2004 Cohn et al. 514,248 Colorado, a body corporate, Denver, 6,797.472 B1 9/2004 Liggett ......... ... 435/6 6,821,724 B1 1 1/2004 Mittman et al. ... 435/6 CO (US) 6,861.217 B1 3/2005 Liggett ......... ... 435/6 7,041,810 B2 5/2006 Small et al. ... ... 435/6 (*) Notice: Subject to any disclaimer, the term of this 7, 195,873 B2 3/2007 Fligheddu et al. ... 435/6 patent is extended or adjusted under 35 7,211,386 B2 5/2007 Small et al. ....... ... 435/6 7,229,756 B1 6/2007 Small et al.
    [Show full text]
  • Long Acting, Reversible Veterinary Sedative and Analgesic And
    University of Kentucky UKnowledge Veterinary Science Faculty Patents Veterinary Science 7-11-2006 Long Acting, Reversible Veterinary Sedative and Analgesic and Method of Use Thomas Tobin University of Kentucky, [email protected] Right click to open a feedback form in a new tab to let us know how this document benefits oy u. Follow this and additional works at: https://uknowledge.uky.edu/gluck_patents Part of the Veterinary Medicine Commons Recommended Citation Tobin, Thomas, "Long Acting, Reversible Veterinary Sedative and Analgesic and Method of Use" (2006). Veterinary Science Faculty Patents. 14. https://uknowledge.uky.edu/gluck_patents/14 This Patent is brought to you for free and open access by the Veterinary Science at UKnowledge. It has been accepted for inclusion in Veterinary Science Faculty Patents by an authorized administrator of UKnowledge. For more information, please contact [email protected]. US007074834B2 (12) United States Patent (10) Patent N0.: US 7,074,834 B2 Tobin (45) Date of Patent: Jul. 11, 2006 (54) LONG ACTING, REVERSIBLE VETERINARY 4,742,054 A 5/1988 Naftchi SEDATIVE AND ANALGESIC AND METHOD 4,950,648 A 8/1990 Raddatz et a1. OF USE 5,635,204 A * 6/1997 GevirtZ et a1. ............ .. 424/449 5,942,241 A 8/1999 Chasin et a1. (75) Inventor: Thomas Tobin, Lexington, KY (US) 5,958,933 A 9/1999 Naftchi (73) Assignee: University of Kentucky Foundation, OTHER PUBLICATIONS Lexington, KY (US) MEDLINE AN 20000025586, Veveris et al, Brit. J. Pharmacol, 128 (5), 1089-97, Nov. 1999, abstract.* ( * ) Notice: Subject to any disclaimer, the term of this Veterinary Pharmacology and Therapeutics, Adams, pp.
    [Show full text]